UNSPSC 51152057: Fenyramidol hydrochloride

This classification denotes a muscle relaxant with the molecular formula C13H14N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M574V6XQH7, chemically known as benzyl alcohol, alpha-((2-pyridylamino)methyl)-, monohydrochloride but more generally known as fenyramidol hydrochloride, which bears US NIH Compound Identifier 9469. European Medicines Agency schedules Fenyramidol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02134MIG.

Most nations, for tariff and trade purposes, schedule fenyramidol hydrochloride under HS 29333999. SMILES: C1CCC(CC1)C(CNC2CCCCN2)O.CL.

UNSPSC 51152057 Fenyramidol hydrochloride is a Commodity code that nominally addresses a specific pharmaceutical active ingredient, but the recent state and local opportunities tagged to it show a mismatch between the code's narrow chemical scope and the actual procurement work being solicited. The code shows little relevant recent activity aligned with fenyramidol hydrochloride as a pharmaceutical input. Instead, the opportunities posted under this code address broader pharmacy benefit program management and opioid-response supply procurement — naloxone procurement, safe drug deactivation systems, and direct-to-manufacturer prescription fulfillment programs — none of which involve fenyramidol hydrochloride as a primary commodity.

Geographic activity is limited to Florida and Texas. Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on vendors' experience with direct contracting for self-insured employers and state agencies and their ability to implement value-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code definition and the solicitations suggests that state and local procurement offices are incorrectly tagging these opportunities, or that the code has been repurposed in practice to capture pharmaceutical procurement more broadly.